Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response by Matsumiya, Magali et al.
Matsumiya et al. BMC Infectious Diseases 2014, 14:314
http://www.biomedcentral.com/1471-2334/14/314RESEARCH ARTICLE Open AccessInflammatory and myeloid-associated gene
expression before and one day after infant
vaccination with MVA85A correlates with induction
of a T cell response
Magali Matsumiya1*, Stephanie A Harris1, Iman Satti1, Lisa Stockdale1, Rachel Tanner1, Matthew K O’Shea1,
Michelle Tameris2, Hassan Mahomed3,4, Mark Hatherill2, Thomas J Scriba2, Willem A Hanekom2, Helen McShane2
and Helen A Fletcher1,5*Abstract
Background: Tuberculosis (TB) remains a global health problem, with vaccination likely to be a necessary part of a
successful control strategy. Results of the first Phase 2b efficacy trial of a candidate vaccine, MVA85A, evaluated in
BCG-vaccinated infants were published last year. Although no improvement in efficacy above BCG alone was seen,
cryopreserved samples from this trial provide an opportunity to study the immune response to vaccination in this
population.
Methods: We investigated blood samples taken before vaccination (baseline) and one and 28 days post-vaccination
with MVA85A or placebo (Candin). The IFN-γ ELISpot assay was performed at baseline and on day 28 to quantify the
adaptive response to Ag85A peptides. Gene expression analysis was performed at all three timepoints to identify early
gene signatures predictive of the magnitude of the subsequent adaptive T cell response using the significance analysis
of microarrays (SAM) statistical package and gene set enrichment analysis.
Results: One day post-MVA85A, there is an induction of inflammatory pathways compared to placebo samples.
Modules associated with myeloid cells and inflammation pre- and one day post-MVA85A correlate with a higher
IFN-γ ELISpot response post-vaccination. By contrast, previous work done in UK adults shows early inflammation
in this population is not associated with a strong T cell response but that induction of regulatory pathways inversely
correlates with the magnitude of the T cell response. This may be indicative of important mechanistic differences in
how T cell responses develop in these two populations following vaccination with MVA85A.
Conclusion: The results suggest the capacity of MVA85A to induce a strong innate response is key to the initiation of
an adaptive immune response in South African infants but induction of regulatory pathways may be more important
in UK adults. Understanding differences in immune response to vaccination between populations is likely to be an
important aspect of developing successful vaccines and vaccination strategies.
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Tuberculosis (TB) is a major global health problem with
an estimated 8.6 million new cases and 1.3 million
deaths in 2012 [1]. Effective vaccination is likely to be
necessary for the long-term control of the TB epidemic
however Bacille Calmette-Guerin (BCG), the only cur-
rently licensed vaccine, provides variable protection
against pulmonary disease [2]. Despite high BCG cover-
age, the incidence of TB remains high in endemic coun-
tries. Research efforts into new TB vaccines have focused
largely on two strategies; either to modify BCG or replace
it with an attenuated strain of Mycobacterium tuberculosis
(M.tb), or to improve the protection provided by BCG
through prime-boost regimes, often using viral vectors ex-
pressing TB antigens to enhance the pool of circulating
memory cells primed by vaccination with BCG [3]. Twelve
novel TB vaccines are currently in clinical trials, including
two in Phase 2b efficacy studies [1]. The results of the first
efficacy trial of a novel vaccine, Modified Vaccinia virus
Ankara expressing antigen 85A (MVA85A) were pub-
lished in early 2013 [4].
Although the efficacy of boosting BCG with MVA85A
was not superior to that of BCG alone, the study dem-
onstrated that a trial of a novel TB vaccine is feasible in
a high burden setting. Furthermore, the collection of
blood samples from all infants during the trial will en-
able research into the mechanisms of disease risk and
response to vaccination in this setting. Previous studies
with MVA85A have shown it to be safe and immuno-
genic in several diverse populations including adults
without or with latent TB infection in the UK; healthy,
latently infected and HIV-infected adults in Africa and
healthy adolescents, children and infants in Africa [5-8].
The vaccine shows a quantitatively lower immunogen-
icity in African adults and in younger children and in-
fants in Africa compared to UK adults [4]. In all trials to
date, MVA85A induces antigen-specific Th1 and Th17
cells, believed to be important in protection against tuber-
culosis [9-11]. If, as has been suggested [12], low T cell re-
sponses to vaccination in this trial contributed to the lack
of vaccine efficacy, understanding the mechanisms deter-
mining the magnitude of the response to vaccination is
important to the development of an improved vaccine.
Several studies published in the last five years have
demonstrated the power of genomics approaches in un-
derstanding the molecular mechanisms of the immune
response to vaccination [13-16]. Work using the yellow
fever vaccine, YF-17D, identified a gene expression sig-
nature in circulating leukocytes of vaccinated volunteers
shortly after vaccination which could predict the magni-
tude of the subsequent CD8+ T cell response [13]. Follow-
up studies have yielded further mechanistic insight,
showing that activation of the nutrient sensor GCN2 in
dendritic cells following vaccination leads to increasedantigen presentation and the development of a stronger
immune response [17]. Similar approaches have been
used by other groups and are beginning to reveal some
of the factors contributing to the variability of the hu-
man immune response. The data show the importance
of innate pathways in determining the magnitude of
subsequent adaptive immune responses with a role for
the stress response and gut microbiota in particular
[18]. The cellular environment and its modification by
vaccines and adjuvants are determined by many factors,
underscoring the large variation seen in the immune re-
sponse to vaccines across individuals and populations.
Understanding the differences in immune responses in
different groups is key to developing targeted approaches
to vaccination. The immune system changes with age,
with a decrease in response to vaccination often noted
in the elderly [19], though a recent study found no de-
crease in T cell responses in older adults following a
novel MVA-vectored influenza vaccine [20]. Inflamma-
tion, apoptosis and immune senescence have all been
linked to lower responses to vaccination in this age
group [16,21]. As the population of the developed world
continues to age, understanding these factors will be im-
portant in developing effective vaccination strategies. At
the other end of the spectrum are the immature immune
systems of infants, which also differ to those of adults
[8,22]. Although children and infants, particularly in the
developing world, are the target population for many
vaccines against infectious diseases, the factors under-
pinning the immune response to vaccination in this
population remain poorly characterized. Understanding
the immune response to vaccination in infants living in
areas with a high burden of disease, and how this differs
from the immune response of healthy, young adults liv-
ing in areas of lower disease prevalence –but in whom
early testing of vaccines is usually carried out- is there-
fore a crucial component in the development and early
selection of many of the vaccines in development.
In this study, we have analysed gene expression signa-
tures pre- and post-vaccination in infants from the
MVA85A Phase 2b efficacy trial who did not develop TB
disease during the trial (non-cases) and correlated these
changes to the antigen-specific T cell response to vaccin-
ation, as measured by IFN-γ ELISpot to Ag85A peptides,
in an effort to understand the variability in response to
vaccination in this setting. Finally, we compare these
findings with previous work performed in UK adults re-
ceiving the same vaccine [23], in an effort to characterise
some of the differences between these populations.
Methods
Origin of samples
Samples used in these experiments were cryopreserved
peripheral blood mononuclear cells (PBMC) or whole
Table 2 Differentially expressed genes 1 day post-
vaccination: MVA85A vs Candin
PROBE_ID SYMBOL Fold change AveExpr adj.P.Val
ILMN_1791759 CXCL10 3.2 7.18 0.04
ILMN_1799848 ANKRD22 2.61 6.65 0.04
ILMN_1656310 INDO 2.53 5.68 0.04
ILMN_2114568 GBP5 2.52 8.7 0.02
ILMN_2132599 ANKRD22 2.46 7.09 0.04
ILMN_3239965 IDO1 2.35 6.17 0.04
ILMN_3247506 FCGR1C 2.13 6.59 0.04
ILMN_1782487 LOC400759 1.96 5.38 0.01
ILMN_2066849 FAM26F 1.89 5.99 0.04
ILMN_1809086 XRN1 1.74 6.83 0.04
ILMN_2053527 PARP9 1.67 6.81 0.04
ILMN_1769520 UBE2L6 1.61 11.07 0.04
ILMN_1707979 CARD17 1.57 5.07 0.04
ILMN_2326509 CASP1 1.57 8.86 0.04
ILMN_1671452 MRPL44 1.5 6.05 0.04
ILMN_1700671 ETV7 1.49 4.83 0.04
ILMN_1678454 CASP4 1.48 9.83 0.04
ILMN_1715401 MT1G 1.43 4.78 0.01
ILMN_3238525 CARD17 1.35 4.6 0.04
ILMN_1693287 POMP 1.32 9.68 0.04
ILMN_1761159 ESYT1 −1.34 8.78 0.05
ILMN_1693410 BRI3BP −1.37 6.56 0.04
ILMN_1774828 VEZT −1.4 5.72 0.04
ILMN_3236036 LOC283663 −1.41 5.39 0.04
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mised, placebo-controlled Phase 2b efficacy trial of a
candidate TB vaccine, MVA85A, in BCG-vaccinated, HIV-
negative South African infants (South African National
Clinical Trials Register DOH-27-0109-2654, Clinical-
Trials.gov NCT00953927). Infants were randomized to
receive either one dose of MVA85A (1 × 108 plaque
forming units in 0.06 mL) or an equal volume of Candida
skin test antigen (Candin, AllerMed, USA) as placebo
at 4–6 months of age [4]. The trial was approved by the
University of Cape Town Faculty of Health Sciences
Human Research Ethics Committee, Oxford University
Tropical Research Ethics Committee, and the Medicines
Control Council of South Africa. Parents or legal guard-
ians provided written, informed consent. Storage of sam-
ples for exploratory immunological analyses was fully
ethically approved.
The samples used in this study were selected from a
subset of 100 infants who had a small blood sample
taken one day post-vaccination. The samples were se-
lected to exclude cases (infants who went on to develop
TB disease) and controls (selected to demographically
match the cases), which will be used in a future study
looking at correlates of risk of TB disease. Therefore
none of the samples used in this study were taken from
infants diagnosed with TB during the course of the trial.
Cells were collected 0–7 days pre- and 28 days post-
vaccination with MVA85A/placebo in cell preparation
tubes with sodium heparin (CPT; Vacutainer; BD) and
PBMC separated and cryopreserved. The cells were thawed
and stimulated as detailed below. One day post-vaccination,
50-300 μL of whole blood was collected directly via heel
prick into a tube filled with RLT buffer (RNeasy kit, Qiagen)
containing 10 μL/mL β-mercaptoethanol using a BD
Quikheel Lancet. The sample was immediately frozen
and RNA extracted as detailed below.
Cell thawing
Cryopreserved PBMC were rapidly thawed in a 37°C
waterbath and transferred to a 15 mL Falcon tube con-
taining 10 mL R10 (RPMI, 10% FCS, 1% L-glutamine,
1% Pen-Strep and 1% sodium pyruvate). PBMC wereTable 1 Samples processed for each assay as part of
this study
Assay Samples
processed
No. of
infants
GEX: unstimulated PBMC days 0 and 28 60 30
GEX: whole blood day 1 82 82
GEX: Ag85A peptide-stimulated PBMC days 0 and 28 20 10
IFN-γ ELISpot (unstim, PHA, 85A) days 0 and 28 99 50
RNA-Sequencing: unstimulated PBMC days 0 and 28 12 6
GEX: gene expression analysis using Illumina Human HT-12 v4 microarray beadchips.
Day 0: day of vaccination with MVA85A/Candin placebo.pelleted, supernatants discarded and resuspended in
10 mL R10 with 20 μL Benzonase (Merck Chemicals
Ltd.) and rested overnight at 37°C, 5% CO2. PBMC were
counted on a Casy Counter (Roche) and split into ap-
propriate volumes for each assay. Not all assays were
performed on all samples.
Ex-vivo IFN-γ ELISpot assay
The ex-vivo IFN-γ ELISpot assay was performed on thawed
PBMC samples collected pre-vaccination and 28 days post-ILMN_3256478 LOC100129034 −1.41 5.38 0.04
ILMN_3240997 ARAP3 −1.43 5.7 0.04
ILMN_1767612 BBS2 −1.44 5.6 0.04
ILMN_1775542 FAIM3 −1.45 9.66 0.04
ILMN_3251155 PCBP2 −1.48 5.49 0.01
ILMN_1772876 ZNF395 −1.5 6.21 0.04
ILMN_3305938 SGK1 −1.56 6.59 0.04
ILMN_1731064 CABC1 −1.59 6.1 0.02
ILMN_3229324 SGK1 −1.6 6.3 0.04
Unstimulated whole blood, genes identified using the R package limma.
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were stimulated in triplicate with a pool of Ag85A peptides,
consisting of 66 15mers, overlapping by 10 amino acids
(2 μg/ml) (Peptide Protein Research).Gene expression assays
PBMC from pre-vaccination and 28 days post-vaccination
were incubated for 12 hours with either R10 media alone
(unstimulated) or pooled Ag85A peptides as described for
the ELISpot (2 μg/mL). After 12 hours supernatant was
removed and the PBMC resuspended in 350uL RLT buffer
(Qiagen) containing 10 μL/mL β-mercaptoethanol and
frozen at -20C.Figure 1 Heatmap of differential gene expression 1 day post vaccinat
vaccination with either MVA85A or a Candin placebo. Colors at the top sho
on the basis of differential expression between the two groups (fdr < 0.05).
Red indicates up-regulated mRNA, blue indicates downregulated.Blood in RLT buffer was thawed and RNA extracted
using the RNeasy kit (Qiagen) according to manufac-
turer’s instructions, including the optional protocol for
DNA digest (RNase-free DNase kit, Qiagen). The proto-
col was modified in the following way for the heelprick
samples due to the small volume of whole blood col-
lected: 80% ethanol was added to precipitate the RNA
(rather than the recommended 70%) and an extra wash with
350 μL RW1 buffer was performed prior to DNA digest.
Messenger RNA was amplified from the total RNA
using the Illumina Totalprep kit (Ambion) according to
manufacturer’s instructions. RNA quantity and quality was
assessed using a Nanodrop ND-1000 Spectrophotometer
and an Agilent Bioanalyser (Agilent RNA 6000 Nano Kit).ion. Heatmap showing changes in gene expression one day post-
w vaccination: MVA85A (blue) or Candin (red). Genes were selected
Clustering using euclidean distance and average clustering methods.
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Illumina Human HT-12 v4 beadchips as specified in the
manufacturer’s instructions. Beadchips were scanned on
an Illumina iScan machine and data extracted using the
GenomeStudio software.
RNA-Seq was performed on pre- and post-vaccination
PBMC from 6 infants (12 samples). Total RNA was sent
to the Beijing Genomics Institute (BGI). Libraries were
constructed using the TruSeq kit (Illumina) and se-
quenced on a HiSeq2000 sequencer, using paired-end
reads of 90 bp and 30 M sequencing depth. Quality con-
trol was performed and the reads aligned to the genome
hg19, downloaded from UCSC (http://genome.ucsc.edu/),
using SOAPaligner2.21 with the following constraints:
maximum number of mismatches allowed on one read is
5 bp, no gaps allowed, only repeat hits reported.
Data analysis
Ex vivo IFN-γ ELISpot assay
Phytohaemagglutinin (PHA) (Sigma) was used as a positive
control and unstimulated wells were used as a measure of
background IFN-γ production. Results are reported as spot
forming cells (SFC) per million PBMC, calculated by sub-
tracting the mean of the unstimulated wells from the mean
of triplicate antigen wells and correcting for the number of
PBMC in the well. An ELISpot response was deemed posi-
tive if the average count in the positive control wells was at
least twice that in the negative control wells and at least 5
spots more than the negative control wells.
Illumina microarray
The R package arrayQualityMetrics [24] was used to as-
sess sample quality. 82 heelprick samples and all PBMC
samples passed quality control. The R package limma was0
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Figure 2 Stimulation of PBMC with Ag85A peptide pools. (a) IFN-γ ELI
vaccinated infants. Responses are significantly higher in the MVA85A group, 4
unstimulated (b) and 85A peptide-stimulated (c) PBMC. Squares = pre-vaccina
Dashed lines indicate a positive ELISpot response (x = 15) and elevated expreused to perform background correction and normalization
and the gene list was filtered using the gene filter pack-
age to remove genes with an expression IQR < 0.3 (log2
transformed). Lists of differentially expressed genes
were generated using limma (p-value cut-off of 0.05
after Benjamini-Hochberg correction [25-27]).
The package Significance Analysis of Microarrays
(SAM) was used to rank genes correlating with the IFN-
γ ELISpot response according to the strength of the cor-
relation [28-30]. The ranked gene list was then inputted into
Broad Institute gene set enrichment analysis programme
(GSEA) [31,32] as an externally supplied preranked list.
The reference gene set used was the Blood Transcrip-
tion Modules compiled by Li et al. [33]. The significance
of module enrichment was assessed by permutation in the
GSEA program.
All heatmaps were generated in R, using Euclidean
distance and average linkage as methods to calculate the
distance matrix and hierarchical clustering respectively.
Where correlations are shown, these use the Pearson
product–moment correlation coefficient.RNA sequencing
Genes for which the reads per kilobase per million value
(rpkm) was <1 in over 40% of samples were excluded.
RPKM was calculated as (10^9*C)/(N*L) where C = number
of reads uniquely mapped to transcript, N = total number
of uniquely mapped reads in sample and L =maximum
length of transcript. Raw counts were then analysed in the
R package limma and converted to log2 transformed counts
per million. These values were compared to the gene ex-
pression values for the equivalent samples obtained by
microarray analysis.0 10 20 30 40 50
6
7
8
9
10
15 20 25
Spot of PBMC taken pre- or post-vaccination in MVA85A or candin-
weeks post-vaccination (Wilcoxon test, p < 0.05). b,c. STAT1 expression in
tion, circles = 28 days post-vaccination; red = candin, blue =MVA85A.
ssion of STAT1 (y = 9.5).
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Gene expression omnibus: GSE56559 (day 1 heelprick,
South African infants), GSE56561 (PBMC, South African
infants) GSE40719 (UK adults).
Results and discussion
Table 1 shows the number of samples used in each assay
in this study.
MVA85A induces an inflammatory signature one day
post-vaccination
Illumina microarray gene expression analysis of 82
whole blood samples taken one day post-vaccination
(37 MVA85A, 45 Candin placebo) identified 32 differ-
entially expressed genes. These genes were largelyTable 3 Differentially expressed genes following Ag85A stimu
Vaccinated infants: day 28- day-7
SYMBOL logFC Fold change adj.P.Val
LOC400759 2.04 4.11 0.0047
GBP5 2.16 4.46 0.0079
LOC730249 1.93 3.82 0.0079
WARS 1.37 2.58 0.0079
ANKRD22 1.67 3.19 0.018
GBP4 1.4 2.63 0.018
WARS 1.25 2.38 0.018
TAP1 0.79 1.73 0.0234
AIM2 1.05 2.07 0.0251
PSME2 0.72 1.65 0.0251
CXCL9 1.63 3.09 0.0259
GBP1 1.9 3.72 0.0349
STAT1 1.15 2.22 0.0354
STAT1 1.32 2.49 0.0476
STAT1 0.92 1.89 0.0746
GBP1 1.87 3.66 0.0911
CD38 0.8 1.74 0.0925
CXCL10 2.3 4.92 0.1295
LAP3 1.13 2.19 0.1295
CEACAM1 0.96 1.95 0.1412
PARP14 0.71 1.63 0.1412
IFNG 1.67 3.19 0.1599
PBMC stimulated for 12 hours with Ag85A peptide pools, genes identified using theassociated with the immune response (differentially
expressed genes are shown in Table 2 with genes asso-
ciated with the immune response highlighted in bold).
Hierarchical clustering showed that infants fall into
three clusters with a mixed MVA85A/Candin cluster
exhibiting a moderate level of expression of inflamma-
tory genes (Figure 1). This analysis shows MVA85A-
vaccinated infants exhibit a more inflammatory gene
expression profile than those in the placebo group how-
ever the range is large in both groups and there is an
overlap between the two groups. This overlap could be
due to the immunomodulatory properties of Candin,
which induces inflammation and may lead to functional
reprogramming of monocytes associated with protec-
tion from subsequent infection [34].lation post-MVA85A vaccination
Day 28 samples: vaccinated- placebo
SYMBOL logFC Fold change adj.P.Val
LOC400759 2.71 6.55 0.012
STAT1 2.69 6.46 0.012
STAT1 2.31 4.96 0.012
CXCL10 3.41 10.64 0.015
CCL8 4.02 16.21 0.027
GBP4 2.19 4.55 0.027
CXCL9 1.95 3.86 0.027
STAT1 1.78 3.44 0.027
WARS 1.69 3.23 0.027
IFI35 1.49 2.8 0.027
WARS 1.73 3.31 0.03
GBP1 2.86 7.28 0.031
PARP9 1.56 2.94 0.031
FBXO6 1.84 3.57 0.037
PARP9 1.46 2.75 0.051
PARP14 1.24 2.36 0.051
PSME2 1.12 2.17 0.051
GBP5 2.65 6.3 0.058
EPSTI1 1.51 2.85 0.058
GBP1 3.01 8.05 0.062
IFNG 2.17 4.51 0.062
P2RX7 1.77 3.42 0.062
SAMD9L 1.37 2.58 0.062
PTER 1.18 2.27 0.062
UBE2L6 1.14 2.21 0.076
IFIT3 2.35 5.09 0.08
SNHG5 −1.17 −2.25 0.08
LOC730249 2.32 5 0.082
PLA2G4C 1.39 2.61 0.082
R package limma. Genes in italics have an adjusted p value 0.05 < p < 0.2).
Figure 3 Modular analysis of genes associated with a higher response to vaccination. Genes whose expression correlate with the IFNg
ELISpot response were identified using the R package SAM (a) and ranked in order of their score. The ranked list was then analysed in GSEA
using the Blood Transcription Modules compiled by Li et al. as the reference gene set [33]. The results of the analysis for genes expressed in
PBMC taken pre-vaccination or whole blood taken one day post-vaccination are shown (b). Length of the bar shows Normalised enrichment
score for each module, number in the bars indicates genes in the test list present ineach reference set. Colour saturation indicates genes present
as a percentage of total genes within the module (signal). Red modules are positively associated with ELISpot response, blue modules are
negatively associated.
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Figure 4 Heatmaps of BTMs associated with a higher response to vaccination. Heatmaps show expression of genes for MVA85A-vaccinated
infants in unstimulated PBMC taken pre-vaccination (a) or whole blood taken one day post-vaccination (b). The colour coding along the top of
the heatmap shows responder (blue) and non-responder (black) infants as measured by IFN-γ ELISpot. Genes are arranged by module (right).
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http://www.biomedcentral.com/1471-2334/14/314The immune response to stimulation with Ag85A peptides
The antigen-specific immune response to Ag85A was
assessed by IFN-γ ELISpot and Illumina microarray gene
expression analysis. Infants vaccinated with MVA85A had
a significantly higher post-vaccination Ag85A-specific
ELISpot response than the Candin group (Figure 2a).
Differentially expressed genes between the vaccine and
placebo groups, and pre- and post-vaccination time
points, are shown in Table 3. The genes induced follow-
ing Ag85A peptide stimulation are all associated with
the STAT1 pathway and exhibit a highly correlated pat-
tern of expression. Furthermore, upregulation of this
pathway occurred in infants who also had a detectable
Ag85A-specific T cell response by IFN-γ ELISpot assay
but not in unstimulated cells or infants who received the
candin placebo (Figure 2b,c). This observation suggests
that, in this population, gene expression analysis does not
add substantial information to that measured by the IFN-
γ ELISpot assay in capturing the response to Ag85A pep-
tide stimulation following MVA85A vaccination.
A proportion of infants did not respond to antigenic
stimulation with Ag85A peptides following MVA85A
vaccination. This lack of response was observed both by
IFN-γ ELISpot and gene expression analysis. It has been4 6 8
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Figure 5 Comparison of gene expression values measured by beadchip
Seq and microarray data of 12 unstimulated PBMC samples for 74 genes usedsuggested that low or absent responses to MVA85A may
be one explanation for the lack of efficacy observed in
the trial [12]. Further analysis of cases and controls is
under way to address this question however, in this
smaller study, we next investigated some of the mecha-
nisms underlying the magnitude of the adaptive immune
response which develops following MVA85A vaccination.
Myeloid cells and inflammation are associated with a
higher ELISpot response
The following analyses were performed using only sam-
ples from infants vaccinated with MVA85A, to further
investigate the mechanisms underlying the immune re-
sponse to this vaccine. The R package Significance Ana-
lysis of Microarrays (SAMR) was used to identify genes
whose expression correlated with the Ag85A-specific T cell
frequencies measured 28 days post-vaccination by IFN-γ
ELISpot assay. SAM identifies genes significantly correlat-
ing with a continuous response variable, in this case the
IFN-γ ELISpot, and outputs a positive and negative set of
genes based on the strength of the correlation of each gene
with higher (positive) or lower (negative) values of the
response phenotype [29,35]. Since the IFN-γ ELISpot
responses in this study were very low, we have10 12 14
icroarray
Number of XY pairs=74
Pearson's r=0.77
95% confidence interval=0.66-0.85
P-value (two-tailed)=4.4e-16
microarray and RNA sequencing. Plot of median values from the RNA-
in the modular analysis. Significance assessed using Pearson’s correlation.
Table 4 Comparison of differentially expressed genes in
South African infants and UK adults post-MVA85A
Fold change
SYMBOL RSA infants UK adults
CXCL10 3.2 6.5
ANKRD22 2.6 2.0
INDO 2.5 1.3
GBP5 2.5 2.2
ANKRD22 2.5 1.7
IDO1 2.4 1.4
FCGR1C 2.1 1.7
LOC400759 2.0 2.1
FAM26F 1.9 1.8
XRN1 1.7 1.0
PARP9 1.7 1.8
UBE2L6 1.6 1.6
SGK1 −1.6 1.1
CABC1 −1.6 −1.3
CARD17 1.6 1.2
CASP1 1.6 1.7
SGK1 −1.6 1.1
MRPL44 1.5 1.1
ZNF395 −1.5 −1.3
ETV7 1.5 1.0
CASP4 1.5 1.2
PCBP2 −1.5 −1.2
FAIM3 −1.5 −1.3
South African infants: unstimulated whole blood taken 1 day post-vaccination.
UK adults: unstimulated PBMC taken 2 days post-vaccination. All genes are
differentially expressed between MVA85A and candin vaccinated infants
(fdr < 0.05); genes in bold are also significantly different between day 0 and
day 2 in UK adults vaccinated with MVA85A.
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responders. An ELISpot response was deemed positive
if the average count in the positive control wells was at
least twice that in the negative control wells and at least
5 spots more than the negative control wells [36]. Sets
of correlating genes pre-vaccination and one day post-
vaccination were generated and ranked according to
their significance score (Figure 3a). This ranked list of
genes was then analysed using the Broad Institute Gene
Set Enrichment Analysis PreRanked function, using the
Blood Transcription Modules defined by Li et al. as a
reference gene set [33]. Pre-vaccination, responder in-
fants have an over-representation of genes enriched in
monocytes, activated dendritic cells and neutrophils as
well chemokines and inflammatory pathways (Figure 3b).
One day post-vaccination, there is a negative association
between lymphoid cells and the subsequent development
of an ELISpot response (Figure 3c). Moreover, there is
positive enrichment of gene sets associated with myeloid
cells, inflammation and an antiviral response. The expres-
sion pattern of these clusters and their relationship to the
ELISpot response is shown in heatmaps in Figure 4.
Higher expression of genes associated myeloid cells and
inflammation pre- and 1 day post-vaccination are both as-
sociated with the development of an antigen-specific T cell
response to vaccination with MVA85A, suggesting the
ability of MVA to induce a strong innate response is key
to its function as a vaccine vector in this population. Add-
itionally, higher expression of genes associated with activa-
tion of lymphoid cells such as NK cells and cytotoxic T
cells one day post-vaccination is associated with an absent
ELISpot response 28 days later.
The ratio of myeloid to lymphoid cells has previously
been associated with differences in TB disease risk in
HIV-infected South African adults and susceptibility to
malaria and influenza in other cohorts [37-40] and this
may be another example of an outcome associated with
this ratio. The gene expression profiles associated with
responder infants are present pre-vaccination and show
a strong overlap pre- and one day post vaccination.
This suggests the baseline inflammatory profile of the
infant, including the differing proportion of circulating
leukocytes, is key to determining the response to vac-
cination. This may be influenced by genetic influences
on innate immunity or environmental exposure preced-
ing vaccination, including the response to BCG, which
all infants received at birth. As MVA preferentially in-
fects myeloid cells [41], a higher proportion of myeloid
cells may lead to overall increased viral expression of
Ag85A protein in infants with higher frequencies of
myeloid cells. Conversely, killing of infected myeloid
cells by cytotoxic T cells and NK cells may decrease
antigen expression, inhibiting the development of a re-
sponse to Ag85A.In a subset of samples, the RNA extracted from the
PBMC collected pre- and 28 days post-MVA85A was also
measured by RNA Sequencing, as part of a pilot project
for future studies. Gene expression values as measured in-
dependently by these two methods are highly correlated
(Figure 5), providing a technical validation for this result.
Gene expression signatures correlating with immunogenicity
differ in South African infants and UK adults
We have previously described changes in gene expression
in unstimulated PBMC from UK adults vaccinated with
the same regime: a BCG prime followed by an MVA85A
boost [23,42]. We therefore wanted to compare the obser-
vations made in these two different populations. In the
adults, there was no placebo and PBMC were collected
for gene expression analysis pre-, two and seven days
post-MVA85A. Comparing gene expression to the magni-
tude of the induced T cell response showed a positive
Figure 6 (See legend on next page.)
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Figure 6 Differences in inflammation and regulation: RSA infants and UK adults. a. Expression in unstimulated whole blood 1 day post-
MVA85A of CXCL10 and IDO1 but not CTLA4 correlates with ELISpot response in RSA infants. CTLA4 expression in unstimulated PBMC 2 days
post-MVA85A is inversely correlated with ELISpot response in UK adults but IDO1 and CXCL10 show no significant association. b. In RSA infants,
IDO1 expression correlates positively with CXCL10 and negatively with CTLA4 expression. In UK adults, CTLA4 and IDO1 expression show a positive
association. All tests are Pearson’s correlations.
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tive correlation with regulatory genes including STAT5B
and CTLA4 at day 2 [42]. Table 4 shows the genes differ-
entially expressed in infants one day post-MVA85A (com-
pared to a placebo group at the equivalent timepoint).
Genes in bold were also differentially expressed in UK
adults two days post-MVA85A compared to baseline and
fold changes are shown for both comparisons. In both
populations, CXCL10 had the highest fold change at the
innate timepoint (one or two days post-MVA85A). One
interesting difference is the gene encoding indoleamine
2,3-dioxygenase (probes INDO and IDO1) which is highly
differentially expressed in the infants but not the adults.
Further to this, the relationships between these genes
show interesting differences between the two popula-
tions (Figure 6). In the South African infants, expression
of both CXCL10 and IDO1 one day post-vaccination
correlates with the IFN-γ ELISpot response and with
each other. In the UK adults however, expression of
these genes correlates neither with each other nor with
the IFN-γ ELISpot response. In the UK adults, we have
previously described a negative association between ex-
pression of CTLA4 post-vaccination and the IFN-γ ELI-
Spot response. However, this association was not found
in South African infants. Furthermore, CTLA4 corre-
lated positively with IDO1 in the UK adults but nega-
tively in the South African infants.
Indoleamine 2,3-dioxygenase (IDO1) is an enzyme
catalyzing the first and rate-limiting step in tryptophan
catabolism. This enzyme has multiple physiological ef-
fects, including immunosuppression and regulation of
T cells. In UK adults, expression of IDO1 in PBMC cor-
relates with that of the inhibitory co-receptor CTLA4.
A recent study showing IDO1 is a critical resistance
mechanism in antitumor T cell immunotherapy target-
ing CTLA-4 in a mouse model of melanoma suggests
the interaction between these two genes is an important
component to consider when inducing an immune re-
sponse for therapeutic purposes [43]. In the South African
infants however, we did not observe a correlation between
expression of IDO1 and CTLA4 but IDO1 correlated with
CXCL10 instead, suggesting either a different role for this
enzyme or that inflammatory and regulatory responses are
closely coupled in this population, perhaps to protect
against excessive immune responses.
These disparities suggest there may be important dif-
ferences in the immune response to vaccination in thesetwo populations and in the pathways that determine the
adaptive immune response. However, it is impossible to
determine whether the differences observed are attribut-
able to age or to genetic or environmental differences be-
tween the populations. Furthermore, the post-vaccination
timepoint differed in both cell type (whole blood in the in-
fants, PBMC in adults) and time taken (one or two days
post-MVA85A). PBMC were used in the pre-vaccination
timepoint in both studies. Despite this, the similarities in
the list of differentially expressed genes suggest these com-
parisons are meaningful and warrant further investigation.
UK adults have a stronger innate response to the vac-
cine, however the magnitude of this response does not
predict the magnitude of the antigen-specific response.
By contrast, in the South African infants the magnitude
of inflammatory gene expression one day post-MVA85A
correlated with the ELISpot response at week 4. Further
investigation of these mechanisms and how they differ
between the different populations in which vaccines are
tested and deployed may prove important in future vac-
cine development strategies.
Conclusions
This study has shown an association between high levels
of inflammation and myeloid signatures both pre- and
post-vaccination and the development of the antigen-
specific T cell response to MVA85A in BCG-vaccinated
South African infants. In this population, the capacity of
the vaccine to induce a strong innate response appears
key to its ability to initiate an adaptive immune re-
sponse. Furthermore, we describe differences in the re-
sponse to vaccination with MVA85A in UK adults and
South African infants, suggesting different immune
pathways may determine immune responses in these
two very different cohorts. This study has focused on in-
vestigating the mechanisms underlying vaccine immuno-
genicity, not vaccine-induced protection. Ultimately, an
understanding of both these aspects of vaccination and
how they differ across individuals and populations is
likely to be necessary in achieving protection in the di-
verse groups and areas of the world still plagued by TB.
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